Jovana Komazec is a molecular biologist who studies the genetic basis of rare and monogenic diseases. She earned her degree in Molecular Biology and Physiology from the University of Belgrade’s Faculty of Biology in 2012. In 2020, she completed her PhD at the same institution, focusing on the molecular-genetic mechanisms behind a specific form of diabetes known as Maturity Onset Diabetes of the Young (MODY). Her doctoral work involved identifying known pathogenic variants in relevant genes, discovering and functionally characterizing novel variants, and exploring genotype-phenotype correlations.

Through ongoing lab work and continuous professional development, she has developed strong skills in molecular biology techniques, with particular expertise in next-generation sequencing on the Illumina platform. She applies these methods in both research and diagnostic contexts related to rare diseases.

Currently, she is involved in several projects: the national GlucoAdjust project, which aims to develop small-molecule treatments for GSD Ib and type 2 diabetes by targeting the G6PT protein; the international BETTER project, which supports secure, GDPR-compliant, AI-driven analysis of cross-border health data to advance personalized medicine; and the BRIDGING‑RD, which focuses on strengthening rare disease research through improved biobank interoperability, bioinformatics pipelines, and translational drug discovery. As part of multidisciplinary teams, she contributes to experimental research and the development of biomedical research infrastructure. Her interests also include biobanking, with a focus on standardizing sample collection, improving data management, and increasing the interoperability of research resources.